| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $37,999,995 | 2 | 100 |
Sells | $0 | 0 | 0 |
| ARCH Venture Fund X, L.P. | 10 percent owner | 1 | $20M | 0 | $0 | $20M |
| ARCH Venture Partners XIV, L.P. | 10 percent owner | 1 | $18M | 0 | $0 | $18M |
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
Over the last 12 months, insiders at Aspen Neuroscience Inc. have bought $38M and sold $0 worth of Aspen Neuroscience Inc. stock.
On average, over the past 5 years, insiders at Aspen Neuroscience Inc. have bought $38M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: ARCH Venture Fund X, L.P. (10 percent owner) — $20M. ARCH Venture Partners XIV, L.P. (10 percent owner) — $18M.
The last purchase of 1,200,000 shares for transaction amount of $18M was made by ARCH Venture Partners XIV, L.P. (10 percent owner) on 2026‑11‑02.
| 2026-11-02 | ARCH Venture Partners XIV, L.P. | 10 percent owner | 1.2M 4.747% | $15.00 | $18M | -5.75% | ||
| 2026-11-02 | ARCH Venture Fund X, L.P. | 10 percent owner | 1.33M 5.2745% | $15.00 | $20M | -5.75% |
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |